Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Rating of “Buy” from Analysts

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have been assigned a consensus rating of “Buy” from the eleven research firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation, eight have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $95.25.

A number of research analysts have commented on JANX shares. HC Wainwright restated a “buy” rating and issued a $70.00 price objective on shares of Janux Therapeutics in a research note on Monday, March 3rd. William Blair reaffirmed an “outperform” rating on shares of Janux Therapeutics in a research note on Friday, January 10th. Scotiabank decreased their price objective on Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating for the company in a research report on Friday, February 28th. Wedbush reissued an “outperform” rating and issued a $76.00 target price (up previously from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. Finally, Lifesci Capital raised Janux Therapeutics to a “strong-buy” rating in a report on Friday, December 27th.

Insiders Place Their Bets

In other news, Director Ra Capital Management, L.P. purchased 341,742 shares of the stock in a transaction that occurred on Wednesday, March 5th. The shares were acquired at an average price of $30.64 per share, for a total transaction of $10,470,974.88. Following the acquisition, the director now directly owns 9,658,988 shares in the company, valued at approximately $295,951,392.32. The trade was a 3.67 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Andrew Hollman Meyer sold 3,334 shares of Janux Therapeutics stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $32.15, for a total value of $107,188.10. Following the transaction, the insider now directly owns 82,139 shares of the company’s stock, valued at approximately $2,640,768.85. This represents a 3.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 10,002 shares of company stock worth $348,203. 29.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. lifted its holdings in shares of Janux Therapeutics by 77.7% in the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock valued at $54,000 after purchasing an additional 442 shares in the last quarter. Avanza Fonder AB raised its position in shares of Janux Therapeutics by 17.0% during the 1st quarter. Avanza Fonder AB now owns 3,049 shares of the company’s stock worth $86,000 after purchasing an additional 444 shares during the last quarter. Rhumbline Advisers lifted its stake in Janux Therapeutics by 1.6% in the 4th quarter. Rhumbline Advisers now owns 38,153 shares of the company’s stock valued at $2,043,000 after buying an additional 599 shares in the last quarter. Exchange Traded Concepts LLC grew its holdings in Janux Therapeutics by 20.4% during the 1st quarter. Exchange Traded Concepts LLC now owns 4,043 shares of the company’s stock valued at $109,000 after buying an additional 686 shares during the last quarter. Finally, Kennedy Capital Management LLC increased its position in Janux Therapeutics by 7.9% during the fourth quarter. Kennedy Capital Management LLC now owns 12,713 shares of the company’s stock worth $681,000 after buying an additional 928 shares in the last quarter. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Stock Up 1.4 %

NASDAQ:JANX opened at $32.07 on Friday. The company has a market capitalization of $1.90 billion, a PE ratio of -27.41 and a beta of 3.27. Janux Therapeutics has a 52-week low of $22.52 and a 52-week high of $71.71. The stock’s 50 day moving average price is $30.20 and its 200 day moving average price is $43.23.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. As a group, sell-side analysts anticipate that Janux Therapeutics will post -1.38 EPS for the current fiscal year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.